142 related articles for article (PubMed ID: 29477313)
1. Which Patients Report That Their Urologists Advised Them to Forgo Initial Treatment for Prostate Cancer?
Radhakrishnan A; Grande D; Mitra N; Pollack CE
Urology; 2018 May; 115():133-138. PubMed ID: 29477313
[TBL] [Abstract][Full Text] [Related]
2. Second opinions from urologists for prostate cancer: Who gets them, why, and their link to treatment.
Radhakrishnan A; Grande D; Mitra N; Bekelman J; Stillson C; Pollack CE
Cancer; 2017 May; 123(6):1027-1034. PubMed ID: 28263389
[TBL] [Abstract][Full Text] [Related]
3. Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
Tyson MD; Graves AJ; O'Neil B; Barocas DA; Chang SS; Penson DF; Resnick MJ
JAMA Surg; 2017 Jan; 152(1):27-34. PubMed ID: 27653425
[TBL] [Abstract][Full Text] [Related]
4. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
5. Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists' recommendations for active treatment or active surveillance: a randomized clinical utility trial.
Peabody JW; DeMaria LM; Tamondong-Lachica D; Florentino J; Czarina Acelajado M; Ouenes O; Richie JP; Burgon T
BMC Urol; 2017 Jul; 17(1):51. PubMed ID: 28673277
[TBL] [Abstract][Full Text] [Related]
6. Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer.
Radhakrishnan A; Wallner LP; Skolarus TA; George AK; Rosenberg BH; Abrahamse P; Hawley ST
J Urol; 2022 Sep; 208(3):600-608. PubMed ID: 35522191
[TBL] [Abstract][Full Text] [Related]
7. Physician variation in management of low-risk prostate cancer: a population-based cohort study.
Hoffman KE; Niu J; Shen Y; Jiang J; Davis JW; Kim J; Kuban DA; Perkins GH; Shah JB; Smith GL; Volk RJ; Buchholz TA; Giordano SH; Smith BD
JAMA Intern Med; 2014 Sep; 174(9):1450-9. PubMed ID: 25023650
[TBL] [Abstract][Full Text] [Related]
8. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions.
Ramsey SD; Zeliadt SB; Fedorenko CR; Blough DK; Moinpour CM; Hall IJ; Smith JL; Ekwueme DU; Fairweather ME; Thompson IM; Keane TE; Penson DF
World J Urol; 2011 Feb; 29(1):3-9. PubMed ID: 20959991
[TBL] [Abstract][Full Text] [Related]
9. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
[TBL] [Abstract][Full Text] [Related]
10. Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign.
Friedlander DF; von Landenberg N; Löppenberg B; Noldus J; Lipsitz SR; Cole AP; Abdollah F; Nguyen PL; Choueiri TK; Kibel AS; Trinh QD
J Urol; 2019 Apr; 201(4):728-734. PubMed ID: 30633112
[TBL] [Abstract][Full Text] [Related]
11. When Primary Care Providers (PCPs) Help Patients Choose Prostate Cancer Treatment.
Radhakrishnan A; Grande D; Ross M; Mitra N; Bekelman J; Stillson C; Pollack CE
J Am Board Fam Med; 2017; 30(3):298-307. PubMed ID: 28484062
[TBL] [Abstract][Full Text] [Related]
12. Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
Egger SJ; Calopedos RJ; O'Connell DL; Chambers SK; Woo HH; Smith DP
Eur Urol; 2018 Jun; 73(6):859-867. PubMed ID: 28851582
[TBL] [Abstract][Full Text] [Related]
13. Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS).
Xu J; Bock CH; Janisse J; Woo J; Cher ML; Ginsburg K; Yacoub R; Goodman M
Cancer; 2024 May; 130(10):1797-1806. PubMed ID: 38247317
[TBL] [Abstract][Full Text] [Related]
14. Choosing active surveillance versus curative treatment in a population-based survey of men with low-risk prostate cancer.
Xu J; Janisse J; Goodman M
Ann Fam Med; 2022 Apr; 20(20 Suppl 1):. PubMed ID: 36696653
[TBL] [Abstract][Full Text] [Related]
15. Understanding the Use of Prostate Biopsy Among Men with Limited Life Expectancy in a Statewide Quality Improvement Collaborative.
Abdollah F; Ye Z; Miller DC; Linsell SM; Montie JE; Peabody JO; Ghani KR;
Eur Urol; 2016 Nov; 70(5):854-861. PubMed ID: 27113032
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
[TBL] [Abstract][Full Text] [Related]
17. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
18. Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists.
Kim SP; Karnes RJ; Nguyen PL; Ziegenfuss JY; Han LC; Thompson RH; Trinh QD; Sun M; Boorjian SA; Beebe TJ; Tilburt JC
J Urol; 2013 Jun; 189(6):2092-8. PubMed ID: 23219546
[TBL] [Abstract][Full Text] [Related]
19. Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.
Kim SP; Gross CP; Nguyen PL; Smaldone MC; Shah ND; Karnes RJ; Thompson RH; Han LC; Yu JB; Trinh QD; Ziegenfuss JY; Sun M; Tilburt JC
Med Care; 2014 Jul; 52(7):579-85. PubMed ID: 24926704
[TBL] [Abstract][Full Text] [Related]
20. Physician Recommendations Trump Patient Preferences in Prostate Cancer Treatment Decisions.
Scherr KA; Fagerlin A; Hofer T; Scherer LD; Holmes-Rovner M; Williamson LD; Kahn VC; Montgomery JS; Greene KL; Zhang B; Ubel PA
Med Decis Making; 2017 Jan; 37(1):56-69. PubMed ID: 27510740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
